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SUPPLEMENTARY NOTES
ABSTRACT
Purpose: To define the pharmacokinetics of colistin after colistimethate sodium infusion and use clinical and microbiological data to explore pharmacodynamic relationships between colistin plasma levels, clinical and microbiological outcomes and drug-related toxicities. Research Design: Multi-center, prospective, open-label, un-controlled observational study. Methodology/Technical Approach: Five plasma samples from 60 patients ≥ 18 years of age receiving colistimethate sodium will be collected, frozen and shipped to Ordway Research Institute where they will be analyzed using a liquid chromatography/mass spectrometry/mass spectrometry system to determine free and protein bound levels of colistin A and colistin B. This data will be used to generate pharmacokinetic models. Additionally, clinical data (to include Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE) score, lab values) of enrolled patients, and results of susceptibility testing on Gram negative bacterial isolates will be collected. The pharmacokinetic, clinical and microbiological data will be analyzed using Monte Carlo population modeling to explore pharmacodynamic relationships between plasma levels of colistin and clinical outcomes, microbiological outcomes and drug toxicities. This project is approved, but we will be unable to complete it as our collaborating lab, Ordway Research has closed and our local use of colistin has dropped to the point that we would be unable to achieve our enrollment goals. The pharmacokinetics and pharmacodynamics of colistin are not well defined and the optimal dose and administration interval to maximize clinical benefit while minimizing its serious toxicities are not well understood.
SUBJECT TERMS
This project was designed to evaluate the pharmacokinetics of colistin and study the pharmacodynamic relationship using Monte Carlo mathematical modeling.
However, due to reasons outlined below, we will be unable to complete this protocol.
Body:
The original statement of work is detailed below. As of our last annual review were awaiting second level approval from the MRMC Human Resources Protection Office (HRPO). That was achieved and task 1 listed in the statement of work below has been achieved. However, the remainder of the original tasks outlined in the original statement of work were not achieved due to the following issues:
1) Loss of collaborator. In May of this year we were informed that our collaborating organization, Ordway Research Institute was in bankruptcy. There was hope at that time that our collaborating scientist, Dr George Drusano would be still be able to analyze the blood specimens and perform the statistical analysis once he had found a new place of employment. It has become clear that this will not be the case. 2) Decrease in Multi-drug resistant organisms which would require colistin use. In the past year, our hospitals have noted a continued decline in the number of patients who had an organsism which would require colistin use. 3) Change in microbial resistance. Colistin was one of the few options available for multi-drug resistant organisms, namely Acinetobacter baumannii. More recently, there have been an increasing percentage of what few patients we do have with this organism who have colistin resistance and thus cannot be given this drug/enrolled in this study 4) Changing practice patterns. There has been a trend in the National Capital Area military treatment facilities towards the use of minocycline for multi-drug resistant Acinetobacter baumannii as opposed to colistin, further decreasing the potential pool for enrollment.
As a result of these issues, we will be unable to complete this study. 
Key Research Accomplishments:
Due to issues outlined above, this study will be closed before beginning enrollment.
Reportable Outcomes:
None
Conclusion:
The aims of this project were to gain insight into how best to utilize the antimicrobial colistin to optimize infection outcomes while minimizing toxicity. However, given loss of collaborating organization, change in practice patterns and changing antimicrobial patterns in infections, as well as resistance, we will be unable to complete this study. We have informed our contact at the Military Infectious Diseases Research Program of this issue. As the decision to close the protocol is has occurred immediately prior to this submission deadline, additional paperwork will follow.
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